Figure 2. The distribution of distinct KRAS mutations is compared for pancreatic and lung cancer. So far, KRAS G12C is amenable to treatment with the approved drugs Sotorasib or Adagrasib but this mutant KRAS allele is present in a very low percentage in pancreatic cancer.